A Pfizer-BioNTech preprint published today suggests that their BNT162b2 vaccine will be effective against SARS-CoV2 variants from the U.K. and South Africa, leading to “small differences in viral neutralization” compared with earlier variants.
The U.K variant has been identified in 26 states in the U.S., while the South Africa variant has been found circulating in South Carolina.
The Pfizer and University of Texas Medical Branch scientists conducting the research concluded that modifying the BNT162b2 was unnecessary.
Get the full story from our sister site, Drug Discovery & Development.